Pawłowska Małgorzata, Olczak Anita
Katedra i Klinika Chor6b Zakainych i Hepatologii, Katedra i Klinika Chorüb Zakainych i Hepatologii Collegium Medicum im. L. Rydygiera w Bydgoszczy Uniwersytet Mikolaja Kopernika w Toruniu.
Przegl Epidemiol. 2012;66(1):55-7.
Treatment efficacy ofDAAs is limited in the presence of HCV mutants which revealed amino-acids substitution and drug resistance. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants. We review the factors that determine resistance, the methods of resistance detection and strategies to avoid the selection of resistant variants.
在存在显示氨基酸替代和耐药性的丙型肝炎病毒（HCV）突变体的情况下，直接抗病毒药物（DAAs）的治疗效果有限。由于HCV的高遗传异质性及其快速复制，使用DAA药物进行单药治疗会带来选择耐药变异体的高风险。我们综述了决定耐药性的因素、耐药性检测方法以及避免选择耐药变异体的策略。
